Known targets — ChEMBL curated mechanism
The experimentally established mechanism targets of Enzastaurin. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PRKCB known ✓ | P05771 | 11/20 | 1.00 |
| ▸ | PRKCG | P05129 | 11/20 | 1.00 |
| ▸ | PRKCA | P17252 | 11/20 | 1.00 |
| ▸ | PRKCE | Q02156 | 11/20 | 1.00 |
| ▸ | PRKCH | P24723 | 10/20 | 1.00 |
| ▸ | PRKCD | Q05655 | 10/20 | 1.00 |
| ▸ | CAMK2D | Q13557 | 10/20 | 1.00 |
| ▸ | CAMK2B | Q13554 | 8/20 | 1.00 |
| ▸ | CAMK2G | Q13555 | 8/20 | 1.00 |
| ▸ | CAMK2A | Q9UQM7 | 8/20 | 1.00 |
| ▸ | PRKCZ | Q05513 | 7/20 | 1.00 |
| ▸ | GSK3B | P49841 | 6/20 | 1.00 |
| ▸ | CDK2 | P24941 | 3/20 | 1.00 |
| ▸ | PIM1 | P11309 | 2/20 | 1.00 |
| ▸ | CDK9 | P50750 | 2/20 | 1.00 |
| ▸ | PIP5K1C | O60331 | 1/20 | 1.00 |
| ▸ | RPS6KA5 | O75582 | 1/20 | 1.00 |
| ▸ | RPS6KA4 | O75676 | 1/20 | 1.00 |
| ▸ | STK16 | O75716 | 1/20 | 1.00 |
| ▸ | PAK3 | O75914 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Enzastaurin SCHEMBL29356867 | 1.00 | PRKCG (1.00) | PRKCGPRKCBPRKCAPRKCEPRKCH | |
| Enzastaurin SCHEMBL29371538 | 1.00 | PRKCG (1.00) | PRKCGPRKCBPRKCAPRKCEPRKCH | |
| Enzastaurin SCHEMBL29371570 | 0.99 | PRKCG (1.00) | PRKCGPRKCBPRKCAPRKCEPRKCH | |
| Enzastaurin SCHEMBL4325665 | 0.99 | PRKCG (0.98) | PRKCGPRKCBPRKCAPRKCEPRKCH | |
| Enzastaurin SCHEMBL16934851 | 0.99 | PRKCG (1.00) | PRKCGPRKCBPRKCAPRKCEPRKCH | |
| Enzastaurin SCHEMBL4877354 | 0.99 | PRKCG (1.00) | PRKCGPRKCBPRKCAPRKCEPRKCH | |
| SCHEMBL25988551 | 0.94 | PRKCG (0.89) | PRKCGPRKCBPRKCAPRKCEPRKCH | |
| Hydrochloric Acid SCHEMBL29784988 | 0.86 | PRKCG (0.77) | PRKCGPRKCBPRKCAPRKCEPRKCH | |
| SCHEMBL3158797 | 0.85 | PRKCA (1.00) | PRKCGPRKCBPRKCAPRKCEPRKCH | |
| SCHEMBL6423238 | 0.83 | PRKCG (1.00) | PRKCGPRKCBPRKCAPRKCEPRKCH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 167 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. | 2022-08-11 | — | — | US | claimed |
| WO-2021007551-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2021-01-14 | — | — | WO | claimed |
| EP-3388836-B1 | METHODS FOR PREDICTING SURVIVAL AND TREATMENT SUSCEPTIBILITY OF GLIOBLASTOMA MULTIFORME (GBM) PATIENTS USING CYTOKINE PROFILES | POLYBIOCEPT GMBH (DE) | 2020-11-25 | — | — | EP | claimed |
| EP-3388836-A1 | METHODS FOR PREDICTING SURVIVAL AND TREATMENT SUSCEPTIBILITY OF GLIOBLASTOMA MULTIFORME (GBM) PATIENTS USING CYTOKINE PROFILES | polybliocept GmbH (DE) | 2018-10-17 | — | — | EP | claimed |
| US-20100179175-A1 | USE OF PKC INHIBITORS IN OCULAR DISEASES | SIVAK JEREMY M | 2010-07-15 | — | — | US | claimed |
| EP-2091535-A1 | USE OF PKC INHIBITORS IN TRANSPLANTATION | Novartis AG (CH) | 2009-08-26 | — | — | EP | claimed |
| EP-2056831-A2 | USE OF PKC INHIBITORS IN PARTICULAR INDOLYLMALEIMIDE DERIVATIVES IN OCULAR DISEASES | Novartis AG (CH) | 2009-05-13 | — | — | EP | claimed |
| US-20090062301-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JA K3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | MAIBUCHER AXEL | 2009-03-05 | — | — | US | claimed |
| EP-2004178-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JAK3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | Novartis AG (CH) | 2008-12-24 | — | — | EP | claimed |
| WO-2008073770-A1 | USE OF PKC INHIBITORS IN TRANSPLANTATION | NOVARTIS AG (CH) | 2008-06-19 | — | — | WO | claimed |
| WO-2008024734-A2 | USE OF PKC INHIBITORS IN PARTICULAR INDOLYLMALEIMIDE DERIVATIVES IN OCULAR DISEASES | NOVARTIS AG (CH) | 2008-02-28 | — | — | WO | claimed |
| US-20070232658-A1 | Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction | WAGNER JURGEN | 2007-10-04 | — | — | US | claimed |
| WO-2007107318-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JAK3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | NOVARTIS AG (CH) | 2007-09-27 | — | — | WO | claimed |
| CN-1948313-A | Preparation method of tiemoazoleamine-8-carboxylic acid water soluble derivative, anticancer activity and application in preparing anticancer medicine | TIANJIN BEIFANG SCIENCE AND TE (CN) | 2007-04-18 | — | — | CN | claimed |
| EP-1734952-A1 | PROTEIN KINASE C INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND OF TRANSPLANT REJECTION | Novartis AG (CH) | 2006-12-27 | — | — | EP | claimed |
| WO-2005097108-A1 | PROTEIN KINASE C INHIBITORS FOR THE TREATMENT OF AUTOIMMUNE DISEASES AND OF TRANSPLANT REJECTION | NOVARTIS AG (CH) | 2005-10-20 | — | — | WO | claimed |
| EP-0817627-B1 | PROTEIN KINASE C INHIBITORS | LILLY CO ELI (US) | 2005-03-09 | — | — | EP | claimed |
| US-20250127700-A1 | METHODS OF TREATING HYPERPIGMENTATION DISORDERS | DERMBIONT INC (US) | 2025-04-24 | — | — | US | disclosed |
| WO-2002002116-A2 | THERAPEUTIC TREATMENT OF CANCER WITH A PROTEIN KINASE C INHIBITOR | ELI LILLY AND COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
| WO-2002002094-A2 | USE OF A PROTEIN KINASE C INHIBITOR TO ENHANCE THE CLINICAL EFFICACY OF ANTI-NEOPLASTIC CHEMOTHERAPEUTIC AGENTS AND RADIATION THERAPY | ELI LILLY AND COMPANY (US) | 2002-01-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179175-A1 | USE OF PKC INHIBITORS IN OCULAR DISEASES | PRKCH, PRKAR2B, PRKCB | PRKCB 3/4885PRKCG 7/4885PRKCA 5/4885 |
| US-20070232658-A1 | Protein Kinase C Inhibitors for the Treatment of Autoimmune Diseases and of Transplant Rejiction | PRKCA, PRKCB, PRKCG | PRKCB 2/4885PRKCG 3/4885PRKCA 1/4885 |
| US-20090062301-A1 | PHARMACEUTICAL COMBINATION COMPOSITION COMPRISING AT LEAST ONE PKC INHIBITOR AND AT LEAST ONE JA K3 KINASE INHIBITOR FOR TREATING AUTOIMMUNE DISORDERS | JAK3, PRKD3, JAK1 | PRKCB 11/4885PRKCG 27/4885PRKCA 7/4885 |
| US-20220249504-A1 | LONGEVITY SIGNATURES AND THEIR APPLICATIONS | GLA, LIMS1, GLB1 | PRKCB 924/4885PRKCG 628/4885PRKCA 636/4885 |
| US-20250127700-A1 | METHODS OF TREATING HYPERPIGMENTATION DISORDERS | TYR, ADH1B, ALDH1A2 | PRKCB 1324/4885PRKCG 1057/4885PRKCA 972/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.